Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Rebecca A Boyd"'
Publikováno v:
Clinical and Translational Science. 10:260-270
We carried out a dose-response model-based meta-analysis to assess venous thromboembolism (VTE) and bleeding with factor Xa (FXa) inhibitors (apixaban, edoxaban, rivaroxaban) and a thrombin inhibitor (dabigatran) compared with European (EU) (40 mg q.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::015b02a704d441b7885e061fe0798b8d
https://doi.org/10.1111/cts.12471
https://doi.org/10.1111/cts.12471
Publikováno v:
Pharmacoepidemiology and Drug Safety. 26:603-605
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::077ecf41bcc7c4ee7804e238c751dc45
https://doi.org/10.1002/pds.4163
https://doi.org/10.1002/pds.4163
Autor:
Brenda Cirincione, Masayo Oishi, Charles Frost, Takayo Ueno, Xiaoli Wang, Frank LaCreta, Rebecca A. Boyd, Kenneth G. Kowalski, Jace Nielsen, Wonkyung Byon, Neelima Thanneer, Tarek A. Leil, Amit Roy
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
This analysis describes the population pharmacokinetics (PPK) of apixaban in nonvalvular atrial fibrillation (NVAF) subjects, and quantifies the impact of intrinsic and extrinsic factors on exposure. The PPK model was developed using data from phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc141bc266a71739b681cffc579b2620
https://pubmed.ncbi.nlm.nih.gov/30259707
https://pubmed.ncbi.nlm.nih.gov/30259707
Autor:
Ronald V. Emmons, Brittany A. Cordle, Jessica N. Leesburg, Erik B. Larson, Rebecca S. Boyd, Dakota G. Simpson
Publikováno v:
Geological Society of America Abstracts with Programs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37389a4fb4d46a72e57a01b4d6ff14f4
https://doi.org/10.1130/abs/2018am-320721
https://doi.org/10.1130/abs/2018am-320721
Autor:
Ronald V. Emmons, Rebecca S. Boyd, Dakota G. Simpson, Jessica N. Leesburg, Brittany A. Cordle, Erik B. Larson
Publikováno v:
Geological Society of America Abstracts with Programs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7579a984043c9b23db344579e16a9a00
https://doi.org/10.1130/abs/2018am-320995
https://doi.org/10.1130/abs/2018am-320995
Autor:
Janice Pursley, Donglu Zhang, Ming Chang, Jessie Wang, Thomas Marbury, Rebecca A. Boyd, Xiaoli Wang, Yan Song, Charles Frost, Giridhar S. Tirucherai
Publikováno v:
The Journal of Clinical Pharmacology. 56:628-636
An open-label, parallel-group, single-dose study was conducted to assess the pharmacokinetics, pharmacodynamics, and safety of apixaban in 8 subjects with end-stage renal disease (ESRD) on hemodialysis compared with 8 subjects with normal renal funct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cea6432febf9e9e0b06405c466f9e10
https://doi.org/10.1002/jcph.628
https://doi.org/10.1002/jcph.628
Autor:
Ming Chang, Jessie Wang, Janice Pursley, Rebecca A. Boyd, Wonkyung Byon, Charles Frost, Zhigang Yu, Frank P. LaCreta, Andrew Shenker
Publikováno v:
The Journal of Clinical Pharmacology. 56:637-645
This open-label study evaluated apixaban pharmacokinetics, pharmacodynamics, and safety in subjects with mild, moderate, or severe renal impairment and in healthy subjects following a single 10-mg oral dose. The primary analysis determined the relati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::181e4ebad7cf8ad5e28bafee85909515
https://doi.org/10.1002/jcph.633
https://doi.org/10.1002/jcph.633
Autor:
Scott McBride, Dawei Xuan, Anthony R. Porcari, Rebecca A. Boyd, Philip Wastall, Lorenzo DiCarlo
Publikováno v:
Clinical Pharmacology in Drug Development. 5:13-26
Objective: The objective of this study was to evaluate PD 0348292 safety, pharmacokinetics, and pharmacodynamics in healthy subjects. Methods: Three phase 1 studies were conducted. Studies 1001 and 1021 were single ascending-dose studies in healthy s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44735a59a71d933f09ca8efa4970edde
https://doi.org/10.1002/cpdd.232
https://doi.org/10.1002/cpdd.232
Autor:
Jessie Wang, Clapton Dias, Rebecca A. Boyd, Zhigang Yu, Donglu Zhang, Alan Schuster, Charles Frost, Andrew Shenker, Frank LaCreta, Yan Song, Wonkyung Byon
Publikováno v:
British Journal of Clinical Pharmacology. 79:838-846
Aim Apixaban is an orally active inhibitor of coagulation factor Xa and is eliminated by multiple pathways, including renal and non-renal elimination. Non-renal elimination pathways consist of metabolism by cytochrome P450 (CYP) enzymes, primarily CY
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bf1cb0cff55f2a2a52e6f6bf0147b41
https://doi.org/10.1111/bcp.12541
https://doi.org/10.1111/bcp.12541
Publikováno v:
Geological Society of America Abstracts with Programs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::541f961154db7cf0e9e646d5452559ab
https://doi.org/10.1130/abs/2017am-302450
https://doi.org/10.1130/abs/2017am-302450